PRQR PRQR
Company Profile ↓Company Overview
PRQR (PRQR) is a publicly traded company listed on with a market capitalization of $212.19M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 64.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.32.
Recent Developments
- Dec 2025 Revenue of $15.91M (-15.9% YoY); net profit $-42.18M.
- Trailing 12 Months Year-on-year growth — revenue -15.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 64.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 64.18% |
| 1 Year: | -15.86% |
Stock Price Performance
| 1 Year: | -4.83% |
| 6 Months: | +23.90% |
| 3 Months: | +20.86% |
| 1 Month: | +18.67% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)63.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 64.2% over 5 years.
CONS
- Trading 35.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 4.52M | 3.82M | 2.88M | 4.69M | 2.03M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 15.34M | 16.07M | 14.17M | 13.79M | 15.68M |
| Operating Income | - | -10.82M | -12.25M | -11.28M | -9.10M | -13.65M |
| EBITDA | - | -10.14M | -11.57M | -10.61M | -6.21M | -12.96M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -10.08M | -12.16M | -11.01M | -8.92M | -13.38M |
| Tax Provision | - | 0 | 18.00K | 0 | 1.00K | 0 |
| Net Income | - | -10.08M | -12.18M | -11.01M | -8.92M | -13.38M |
| Diluted EPS | - | -0.10 | -0.12 | -0.10 | - | -0.13 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.59M | 6.51M | 18.91M | 15.91M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 68.75M | 41.30M | 49.38M | 59.35M |
| Operating Income | - | -65.16M | -34.79M | -30.47M | -43.45M |
| EBITDA | - | -56.46M | -24.10M | -24.12M | -38.53M |
| Interest Expense | - | 5.13M | 1.20M | 1.08M | 929.00K |
| Pretax Income | - | -64.11M | -27.81M | -27.96M | -42.16M |
| Tax Provision | - | 96.00K | -78.00K | -197.00K | 19.00K |
| Net Income | - | -64.42M | -28.12M | -27.76M | -42.18M |
| Diluted EPS | - | -0.90 | -0.35 | -0.32 | -0.40 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 171.32M | 137.88M | 167.96M | 112.76M |
| Current Assets | - | 154.46M | 120.99M | 153.84M | 100.13M |
| Cash & Equivalents | - | 94.78M | 118.92M | 149.41M | 92.41M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | 0 | 3.36M |
| Total Liabilities | - | 104.64M | 96.49M | 79.40M | 63.38M |
| Current Liabilities | - | 20.99M | 34.20M | 38.90M | 32.44M |
| Long Term Debt | 39.32M | 4.27M | 4.29M | - | - |
| Total Debt | - | 21.97M | 19.73M | 17.22M | 15.96M |
| Total Equity | - | 67.06M | 41.39M | 88.56M | 49.37M |
| Shares Outstanding | - | 84.25M | 84.25M | 107.71M | 107.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -68.51M | 21.55M | -36.39M | -52.79M |
| Investing Cash Flow | - | -702.00K | 4.28M | -4.07M | -1.02M |
| Financing Cash Flow | - | -30.89M | -2.27M | 70.28M | -1.84M |
| Capital Expenditure | - | -708.00K | -1.37M | -1.42M | -1.02M |
| Free Cash Flow | - | -69.22M | 20.18M | -37.81M | -53.81M |
| Net Change in Cash | - | -100.10M | 23.55M | 29.81M | -55.65M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -1,813.0% | -534.1% | -161.2% | -273.1% |
| Net Margin % | - | -1,792.5% | -431.7% | -146.9% | -265.2% |
| ROE % | - | -96.1% | -67.9% | -31.3% | -85.4% |
| ROCE % | - | -43.3% | -33.6% | -23.6% | -54.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRQR
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on i…
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the evaluable 3 mg/kg and 6 mg/kg cohortsAX-0810 demonstrated up to 8-fold change (6 mg/kg) in total bil…
Undervalued Penny Stocks To Consider In June 2026
Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stocks, penny stocks—often representing smal…
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
Today is shaping up negative for ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders, with the analysts delivering a...
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
Kamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ProQR Announces First Quarter 2026 Operating and Financial Results
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple…
PRQR — Frequently Asked Questions
What is the current share price of PRQR?
As of 2026-08-05 17:25 PDT, PRQR trades at $1.97 on NASDAQ/NYSE. Its 52-week range is $1.37 to $3.05.
What is the market capitalisation of PRQR?
PRQR has a market capitalisation of $212.19M on NASDAQ/NYSE.
What is the P/E ratio of PRQR?
PRQR trades at a trailing price-to-earnings (P/E) ratio of -4.92. Its price-to-book (P/B) ratio is 4.30.
What is the return on equity (ROE) of PRQR?
PRQR has a return on equity (ROE) of -85.44%. Its return on capital employed (ROCE) is -54.09%.
Is PRQR a good stock to buy?
This page provides a data-driven analysis of PRQR, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.